- Home
- ARQT vs NRK Comparison
ARQT vs NRK Comparison
Compare ARQT & NRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARQT
- NRK
- Stock Information
- Founded
- ARQT 2016
- NRK 2002
- Country
- ARQT United States
- NRK United States
- Employees
- ARQT N/A
- NRK N/A
- Industry
- ARQT Biotechnology: Pharmaceutical Preparations
- NRK Trusts Except Educational Religious and Charitable
- Sector
- ARQT Health Care
- NRK Finance
- Exchange
- ARQT Nasdaq
- NRK Nasdaq
- Market Cap
- ARQT 1.1B
- NRK 904.6M
- IPO Year
- ARQT 2020
- NRK N/A
- Fundamental
- Price
- ARQT $13.02
- NRK $10.63
- Analyst Decision
- ARQT Strong Buy
- NRK
- Analyst Count
- ARQT 6
- NRK 0
- Target Price
- ARQT $17.00
- NRK N/A
- AVG Volume (30 Days)
- ARQT 2.3M
- NRK 187.3K
- Earning Date
- ARQT 02-25-2025
- NRK 01-01-0001
- Dividend Yield
- ARQT N/A
- NRK 4.10%
- EPS Growth
- ARQT N/A
- NRK N/A
- EPS
- ARQT N/A
- NRK N/A
- Revenue
- ARQT $138,708,000.00
- NRK N/A
- Revenue This Year
- ARQT $217.37
- NRK N/A
- Revenue Next Year
- ARQT $55.64
- NRK N/A
- P/E Ratio
- ARQT N/A
- NRK N/A
- Revenue Growth
- ARQT 182.84
- NRK N/A
- 52 Week Low
- ARQT $6.99
- NRK $8.95
- 52 Week High
- ARQT $16.20
- NRK $11.09
- Technical
- Relative Strength Index (RSI)
- ARQT 50.16
- NRK 51.93
- Support Level
- ARQT $11.13
- NRK $10.58
- Resistance Level
- ARQT $13.62
- NRK $10.79
- Average True Range (ATR)
- ARQT 1.04
- NRK 0.06
- MACD
- ARQT 0.08
- NRK -0.00
- Stochastic Oscillator
- ARQT 67.26
- NRK 51.47
About ARQT Arcutis Biotherapeutics Inc.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's lead product candidate ZORYVE roflumilast cream, has successfully completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.
About NRK Nuveen New York AMT-Free Quality Municipal Income Fund
Nuveen New York AMT-Free Quality Municipal Income Fund is a closed-end investment company. Its investment objective is to provide current income exempt from regular federal, New York State, and New York City income taxes and from the federal alternative minimum tax applies to individuals and to enhance portfolio value relative to the municipal bond market by investing in tax-exempt municipal bonds that the Fund's investment adviser believes are underrated or undervalued or that represent municipal market sectors that are undervalued.